Lessons for lupus from tumour necrosis factor blockade

Systemic lupus erythematosus (SLE) is a systemic non-organ specific autoimmune disease associated with multiple autoantibodies targeting autoantigens from the nucleus. Given the complex pathophysiology of SLE and the role of TNF alpha in that disease, modulation of TNF alpha (in SLE or non-SLE patie...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2006-01, Vol.15 (11), p.762-767
Main Author: DeBandt, M
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Apoptosis
Apoptosis - drug effects
Arthritis
Autoantibodies - immunology
Cytokines
Dendritic cells
Humans
Ligands
Lupus
Lupus Erythematosus, Systemic - drug therapy
Lupus Erythematosus, Systemic - immunology
Lupus Erythematosus, Systemic - physiopathology
Pathophysiology
Patients
Rheumatology
TNF inhibitors
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - immunology
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic lupus erythematosus (SLE) is a systemic non-organ specific autoimmune disease associated with multiple autoantibodies targeting autoantigens from the nucleus. Given the complex pathophysiology of SLE and the role of TNF alpha in that disease, modulation of TNF alpha (in SLE or non-SLE patients) using TNF blockers could either be detrimental or beneficial in some patients. In this review we will focus on lupus autoantibodies and clinical manifestations after TNF blockade in SLE patients and conversely on drug-induced-SLE in non-SLE patients. Some hypotheses regarding the mechanism of induction of autoantibodies in RA patients treated with TNF blockers are proposed.
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203306071703